Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Allakos Shares Double on AK002 Phase 2 Results and Earnings

Allakos Inc. shares are soaring today as the company reported Q2/19 earnings and announced positive results from its phase 2 study for its AK002 inhibitor used in the treatment of eosinophil and mast cell related diseases. Clinical stage biotech company Allak...
Streetwise Reports | August 7, 2019 |

Analyst Upgrade Ignites Duchenne's Muscular Dystrophy Research Firm's Shares

Solid Biosciences' shares are up by more than 40% today after Chardan Capital Markets upgraded the firm's shares from "neutral" to "buy" and raised its price target from $7.50 to $10.00/share. Duchenne muscular dystrophy (DMD) research firm Solid Biosciences ...
Streetwise Reports | August 20, 2019 |

Aleafia Health CEO Talks Expansion Plans and Progress

(Image via Aleafia Health. Click image to enlarge) When a business strategy works and can be expanded, the smart bet is to double down. That’s the logic in any industry, and the still-growing cannabis market is no different. That&CloseCurlyQuote...
Omri Wallach | September 27, 2019 |

Puma Biotech Shares Up More Than 20% on Q2 Earnings and Breast Cancer Drug Sales

Shares in Puma Biotechnology are trading 20% higher today after the company released Q2/19 earnings and reported positive NERLYNX revenue growth. Biopharmaceutical company Puma Biotechnology Inc. (PBYI:NADSAQ) shares opened more than 20% higher to...
Streetwise Reports | August 14, 2019 |

Fiscal Year 'Reads Well' for Regenerative Medicine Company

The firm's final quarter and full-year results are reviewed in a Ladenburg Thalmann report. In an Aug. 30 research note, Ladenburg Thalmann analyst Jeffrey Cohen reported Mesoblast Ltd.'s (MESO:NASDAQ; MSB:ASX) financial results for Q4/19 and fiscal year 2019 (FY19)...
Streetwise Reports | September 5, 2019 |

FedEx Shares Down 13.5% on Earnings and Global Trade Concerns

FedEx Corp. shares are trading much lower today after it reported Q1/20 earnings. The firm confirmed it will raise prices by 4.9% to 5.9% in January 2020. After the close of trading yesterday express air freight carrier FedEx Corp. (FDX:NYSE) announced consolidated...
Streetwise Reports | September 19, 2019 |

Prospera Energy's path to cleaner, more profitable energy production

Prospera Energy Inc. (TSXV:PEI) is a clean and safe energy producer with oil and gas operations in Western Canada. The company applied modern and cost-effective horizontal drilling techniques to reduce the environmental footprint of numerous vertical wells. Here to ...
Brieanna McCutcheon | October 3, 2023 |

This stealth rally is about to explode into a huge bull market

It was a "stealth" rally... Over the first couple months of 2010, the U.S. stock market hovered around breakeven. Investors were too busy worrying about Greece's debt crisis, fourth-quarter earnings, and health care reform to notice what was happening over in my c...
Dr. George Huang | October 28, 2012 |

Iovance Biotherapeutics Shares Rise 12% on Updated Phase 2 Melanoma Study Results

Shares of Iovance Biotherapeutics traded 12% higher today after the firm reported updated clinical data from its phase 2 lifileucel metastatic melanoma trial. Just a few days after reporting third quarter 2019 earnings, late-stage biotechnology company Iovance Biothe...
Streetwise Reports | November 12, 2019 |

Canada Asset 'Sale Helps Company Focus on Mexico'

The specifics and benefits of the transaction are addressed in a ROTH Capital Partners report. In a Nov. 22 research note, ROTH Capital Partners analyst Joe Reagor reported that Avino Silver & Gold Mines Ltd. (ASM:TSX.V; ASM:NYSE.MKT; GV6:FSE) agreed to sell its Bra...
Streetwise Reports | December 2, 2019 |
1 2 3 4 5 6 7 8 9 10 ...